Role of GLP-1 agonists in breast cancer survivorship setting

Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential use of GLP-1 or GLP agonist and incretin mimetics during or after cancer therapy, particularly in breast cancer survivors, who are at risk for metabolic disorders such as diabetes and cardiovascular disease. Dr Iyengar notes that while weight loss drugs may be beneficial in the survivorship setting, their use during or immediately after cancer therapy is not currently recommended due to lack of safety data and potential toxicity. Dr Iyengar suggests that further research is needed to fully understand the effects of these medications on cancer treatment outcomes. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.